文献速递炎症性肠病

克罗恩病达标治疗策略的成本效果微模拟模型

A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

本研究建立克罗恩病微模拟模型,比较基于粪便钙卫蛋白的生物标志物监测与基于内镜的达标治疗监测的成本效果。结果显示,在5年时间范围内,内镜监测策略占优;但在1年时间范围内,生物标志物监测策略更具成本效果。最具有成本效果的策略是先进行生物标志物监测,若1年内未达到内镜缓解则转为内镜监测,达到内镜缓解后再回到生物标志物监测。

要点

  • 5年时间范围内,内镜监测策略占优生物标志物监测策略。
  • 1年时间范围内,生物标志物监测策略具有成本效果。
  • 最具有成本效果的策略为先生物标志物监测,1年未达内镜缓解转内镜监测,缓解后转回生物标志物监测。

核心结论

  • 在5年时间范围内,基于内镜的监测策略占优基于生物标志物的监测策略。
  • 最具有成本效果的达标治疗监测策略是先进行生物标志物监测,若1年内未达到内镜缓解则转为内镜监测,达到内镜缓解后再回到生物标志物监测。

研究设计与样本

  • 建立克罗恩病微模拟模型,模拟基于粪便钙卫蛋白的生物标志物监测与基于内镜的监测在达标治疗策略中的应用。
  • 使用已发表文献、3期临床试验患者水平数据和群体估计的治疗药物监测数据生成转移概率、成本和效用。
  • 主要结局为5年时间范围内、支付意愿阈值为每质量调整生命年100,000美元的成本效果。

主要发现

  • 在基础案例模型中,5年时间范围内内镜监测策略占优生物标志物监测策略。
  • 在较短观察期内,生物标志物监测策略逐渐更具成本效果,在1年时间范围内达到成本效果。
  • 治疗药物监测未影响生物标志物监测策略的短期成本效果。
  • 一旦达到内镜缓解,继续生物标志物监测比内镜监测更具成本效果。
  • 混合生物标志物-内镜监测策略在5年时间范围内占优内镜监测策略。

关键数值与推荐

  • 支付意愿阈值为每质量调整生命年100,000美元。
  • 成本效果的最强决定因素为结肠镜检查成本和粪便钙卫蛋白的诊断性能。

临床怎么用

  • 对于克罗恩病达标治疗监测,可考虑先进行生物标志物监测,若1年内未达到内镜缓解则转为内镜监测,达到内镜缓解后再回到生物标志物监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cost-effectiveness of biomarker- vs endoscopy-based treat-to-target monitoring in Crohn's disease (CD) is unknown. METHODS: A microsimulation model for CD was built to simulate biomarker (fecal calprotectin) vs endoscopy-based monitoring in a treat-to-target fashion. Published literature in combination with patient-level data from phase 3 clinical trials and population estimates for therapeutic drug monitoring were used to generate transition probabilities, costs, and utilities. Tracker variables were used to modify downstream probabilities and outcomes based on previous exposures, response patterns, and disease-related complications or surgery history. The primary outcome was cost-effectiveness over a 5-year horizon at a willingness-to-pay threshold of $100,000/quality-adjusted life-year. Probabilistic sensitivity analyses in addition to multiple 1-, 2-, and 3-way microsimulation sensitivity analyses were performed. RESULTS: In the base-case model, the endoscopy-based monitoring strategy dominated the biomarker-based monitoring strategy over a 5-year horizon. Over shorter periods of observation, the biomarker-based monitoring strategy became progressively more cost-effective, with cost-effectiveness achieved for this strategy over a 1-year horizon. Therapeutic drug monitoring did not influence short-term cost-effectiveness of biomarker-based monitoring. Once in endoscopic remission, continued biomarker-based vs endoscopy-based monitoring was more cost-effective. A hybrid biomarker-endoscopy-based monitoring strategy dominated the endoscopy-based monitoring strategy over a 5-year horizon. The strongest determinants for cost-effectiveness were cost of colonoscopy and diagnostic performance of fecal calprotectin. DISCUSSION: The most cost-effective approach for treat-to-target monitoring in CD is up-front biomarker-based monitoring followed by endoscopy-based monitoring if not in endoscopic remission by 1 year and then returning to biomarker-based monitoring once in endoscopic remission.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Dulai PS, Jairath V, Narula N, et al. A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. Am J Gastroenterol. 2021. PMID: 34587127. doi:10.14309/ajg.0000000000001263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。